Curaleaf (OTCMKTS:CURLF) Raised to “Strong-Buy” at Zacks Research

Curaleaf (OTCMKTS:CURLF) was upgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Tuesday,Zacks.com reports.

Curaleaf Stock Down 1.6%

CURLF opened at $9.75 on Tuesday. The firm has a market cap of $2.28 billion, a price-to-earnings ratio of -25.00 and a beta of 1.51. The company has a debt-to-equity ratio of 1.05, a quick ratio of 0.74 and a current ratio of 1.56. The firm’s 50-day simple moving average is $7.56 and its 200-day simple moving average is $7.56. Curaleaf has a twelve month low of $2.83 and a twelve month high of $15.15.

Curaleaf (OTCMKTS:CURLF) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.51. The firm had revenue of $324.23 million during the quarter, compared to the consensus estimate of $316.62 million. Curaleaf had a negative net margin of 7.76% and a negative return on equity of 8.11%. Equities research analysts anticipate that Curaleaf will post -0.31 EPS for the current fiscal year.

Curaleaf Company Profile

Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.

Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.